Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Anticholinergic burden in middle and older age is associated with lower cognitive function, but not with brain atrophy

View ORCID ProfileJ. Mur, View ORCID ProfileR. E. Marioni, View ORCID ProfileT. C. Russ, View ORCID ProfileG. Muniz-Terrera, View ORCID ProfileS. R. Cox
doi: https://doi.org/10.1101/2022.09.04.22279576
J. Mur
1Lothian Birth Cohorts group, Department of Psychology, University of Edinburgh, Edinburgh, UK
2Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
3Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Mur
  • For correspondence: jure.mur{at}ed.ac.uk
R. E. Marioni
2Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. E. Marioni
T. C. Russ
3Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK
4Edinburgh Dementia Prevention, University of Edinburgh, Edinburgh, UK
5Division of Psychiatry, Centre for Clinical Brain Science, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for T. C. Russ
G. Muniz-Terrera
4Edinburgh Dementia Prevention, University of Edinburgh, Edinburgh, UK
6Department of Social Medicine, Ohio University, Athens, Ohio, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G. Muniz-Terrera
S. R. Cox
1Lothian Birth Cohorts group, Department of Psychology, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. R. Cox
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Anticholinergic drugs block muscarinic receptors in the body. They are commonly prescribed for a variety of indications and their use has previously been associated with dementia and cognitive decline.

Methods UK Biobank participants with linked health-care records (n=163,043, aged 40-71 at baseline), for about 17,000 of which MRI data was available, we calculated the total anticholinergic drug burden according to 15 different anticholinergic scales and due to different classes of drugs. We then used linear regression to explore the associations between anticholinergic burden and various measures of cognition and structural MRI, including general cognitive ability, 9 separate cognitive domains, brain atrophy, volumes of 68 cortical and 14 subcortical areas, and fractional anisotropy and median diffusivity of 25 white-matter tracts.

Results Anticholinergic burden was modestly associated with poorer cognition across most anticholinergic scales and cognitive tests (7/9 FDR-adjusted significant associations, standardised betas (β) range: −0.039, −0.003). When using the anticholinergic scale exhibiting the strongest association with cognitive functions, anticholinergic burden due to only some classes of drugs exhibited negative associations with cognitive function, with β-lactam antibiotics (β=-0.035, pFDR<0.001) and opioids (β=-0.026, pFDR<0.001) exhibiting the strongest effects. Anticholinergic burden was not associated with any measure of brain macro- or microstructure (pFDR>0.08).

Discussion Anticholinergic burden is weakly associated with poorer cognition, but there is little evidence for associations with brain structure. Future studies might focus more broadly on polypharmacy or more narrowly on distinct drug classes, instead of using purported anticholinergic action to study the effects of drugs on cognitive ability.

Competing Interest Statement

REM has received consulting fees from the Epigenetic Clock Development Foundation and speaker fees from Illumina. TCR has received fees for medicolegal work from private solicitors. SRC has received speaker fees from the Society of Biological Psychiatry. GMT has received consulting fees for grants funded by the NIH. JM has nothing to disclose.

Funding Statement

This research was funded in whole, or in part, by the Wellcome Trust [108890/Z/15/Z]. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. REM is supported by Alzheimer's Research UK major project grant ARUK-PG2017B-10 and by an Alzheimer's Society major project grant AS-PG-19b-010. JM is supported by funding from the Wellcome Trust 4‐year PhD in Translational Neuroscience-training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. JM and TCR are members of the Alzheimer Scotland Dementia Research Centre funded by Alzheimer Scotland.TCR is employed by NHS Lothian and the Scottish Government and has received grants from the Royal Society of Edinburgh [1689], the Scottish Government, the Chief Scientist Office [NRS NDN and CGA/19/05], the UK National Health Service, and UK Research and Innovation [ES/W001349/1]. SRC is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society [221890/Z/20/Z] and has received grants from Age UK [The Disconnected Mind project], the UK Medical Research Council [MR/R024065/1], the National Institutes of Health [R01AG054628; 1RF1AG073593] and the UK Biotechnology and Biological Sciences Research Council and the Economic and Social Research Council (BB/W008793/1; ES/T003669/1). GMT has received funding from the Medical Research Council Methodology Board.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Research Ethics Committee (REC) of the Univeristy of Edinburgh granted ethical approval for the study (reference 11/NW/0382) and the current analysis was conducted under data application 10279.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Previous version stated that AChB according to "most" drug classes was associated with lower general cognitive ability, although only some demonstrated significant associations. This has now been corrected. Also, "reduced" in the title has been altered to "lower" so as not to suggest repeated/longitudinal measurements.

Data Availability

All data produced in the present study are available upon request from UK Biobank.

https://github.com/JuM24/UKB-AChB-cognition-MRI

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 12, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Anticholinergic burden in middle and older age is associated with lower cognitive function, but not with brain atrophy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anticholinergic burden in middle and older age is associated with lower cognitive function, but not with brain atrophy
J. Mur, R. E. Marioni, T. C. Russ, G. Muniz-Terrera, S. R. Cox
medRxiv 2022.09.04.22279576; doi: https://doi.org/10.1101/2022.09.04.22279576
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Anticholinergic burden in middle and older age is associated with lower cognitive function, but not with brain atrophy
J. Mur, R. E. Marioni, T. C. Russ, G. Muniz-Terrera, S. R. Cox
medRxiv 2022.09.04.22279576; doi: https://doi.org/10.1101/2022.09.04.22279576

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)